A. Scott Paulson
Charles A. Sammons Cancer Center/Texas Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name A. Scott Paulson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04926467 · Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)Baylor Research Institute · recruiting · Pancreatic Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 59 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:28 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol · 20201,327 citationsRCR 56.9
- 458 citationsRCR 44.1
- 323 citationsRCR 26.1
- 220 citationsRCR 18.8
- Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Cancer Discov · 2024124 citationsRCR 13.9
- An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.ESMO Open · 202489 citationsRCR 10.7
- Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.Cancer Gene Ther · 200381 citationsRCR 1.6
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.Nat Commun · 202611 citationsRCR 5.5
- 5 citationsRCR 0.7
- Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.Cancer Invest · 20043 citationsRCR 0.1